Neurocrine Biosciences, Inc.(NBIX): For the most recent quarter end, Neurocrine Biosciences, Inc. reported Annual Earnings of $-0.51. Based on the filings, last years Annual Earnings was, $-1.63. For the most recent quarter end, NBIX reported a surprise Earnings per Share of 7.27% . The consensus estimate for current quarter is $-0.61 and for the current fiscal year, the estimate is $-2.06. For the Next fiscal year, the estimate is $-1.32 based on the consensus.
Neurocrine Biosciences, Inc. has received $-0.61 as the consensus Earnings Estimate for the Quarter ending on Mar 2017 ,According to the estimate provided by 7 Financial Advisor in the Stock Trading Firms. Among 7 Analysts, Bottom line EPS Estimate for the current quarter is $-0.91 while the top line estimate is $-0.31 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -178.57%. Neurocrine Biosciences, Inc. reported better than expected with a surprise EPS of 7.27% or $0.04 during its most recent quarterly earnings. The Actual EPS was $-0.51 compared to the Estimated EPS of $-0.55.
Neurocrine Biosciences Last issued its quarterly earnings results on Feb 14, 2017. The company reported $-0.51 EPS for the quarter, beating the analyst consensus estimate by $ 0.04. Analyst had a consensus of $-0.55.During the same quarter in the previous year, the company posted $-0.34 EPS.
Company has reported several Insider transactions to the SEC, on Feb 8, 2017, Dimitri E. Grigoriadis (Chief Research Officer) sold 727 shares at 43.13 per share price.On Feb 8, 2017, Haig P. Bozigian (Chief Development Officer) sold 963 shares at 43.14 per share price.On Feb 8, 2017, Kyle Gano (Chief Business Development Off) sold 727 shares at 43.15 per share price.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) witnessed a decline in the market cap on Wednesday as its shares dropped 2.96% or 1.3 points. After the session commenced at $43.85, the stock reached the higher end at $44.3375 while it hit a low of $42.58. With the volume soaring to 808,594 shares, the last trade was called at $42.6. The company has a 52-week high of $55.15. The company has a market cap of $3,711 million and there are 87,114,340 shares in outstanding. The 52-week low of the share price is $32.18.
Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The companys neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.